导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.66% | 1221/4773 |
| 近一周 | -1.02% | 1526/5465 |
| 近一月 | -3.43% | 2493/5421 |
| 近一季 | -7.65% | 2913/5231 |
| 近半年 | -3.12% | 2399/4920 |
| 近一年 | 9.78% | 1165/4394 |
| 近两年 | 77.68% | 881/2954 |
| 近三年 | 43.13% | 690/2253 |
| 成立以来 | 138.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.87% 1152/4961 |
19.27% 1308/5312 |
- - |
- - |
| 2025 | 31.60% 1226/4813 |
2.59% 1321/3635 |
2.12% 1838/4076 |
24.44% 1468/4524 |
0.94% 1645/4813 |
| 2024 | 7.74% 1626/3463 |
-2.60% 1388/2808 |
-5.00% 1616/3014 |
15.79% 1625/3129 |
0.57% 1197/3463 |
| 2023 | -5.88% 790/2656 |
7.51% 564/2280 |
-3.84% 923/2385 |
-4.90% 1252/2515 |
-4.26% 938/2655 |
| 2022 | -16.75% 510/2207 |
-12.76% 655/1919 |
2.99% 1232/2016 |
-9.75% 306/2113 |
2.65% 870/2208 |
| 2021 | 20.94% 172/1822 |
-0.87% 401/1255 |
11.19% 388/1330 |
5.85% 254/1466 |
3.66% 407/1822 |
| 2020 | 35.86% 407/1250 |
-2.44% 262/1028 |
19.24% 306/1067 |
11.22% 466/1164 |
5.01% 817/1184 |
| 2019 | 29.69% 497/1092 |
31.55% 199/754 |
-9.63% 674/804 |
2.39% 302/850 |
6.55% 596/918 |
| 2018 | -31.64% 502/834 |
- - |
- - |
- - |
-12.93% 496/691 |
| 2017 | 4.44% 417/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.12% 333/605 |
- - |
- - |
- - |
- - |
| 2015 | 35.82% 58/575 |
- - |
- - |
- - |
- - |
| 2014 | 37.84% 136/237 |
- - |
- - |
- - |
- - |
| 2013 | 16.50% 21/186 |
- - |
- - |
- - |
- - |
| 2012 | -0.29% 121/140 |
- - |
- - |
- - |
- - |
| 2011 | -33.24% 99/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证500指数(LOF)A VS. 长安沪深300非周期A(740101) |